glucagon-like-peptide-1 and Ovarian-Neoplasms

glucagon-like-peptide-1 has been researched along with Ovarian-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for glucagon-like-peptide-1 and Ovarian-Neoplasms

ArticleYear
A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes.
    Lancet (London, England), 2003, Jan-18, Volume: 361, Issue:9353

    Glucagon-like peptide 1 (GLP-1), an insulinotropic hormone normally synthesised in the intestinal mucosa and released in response to a meal, is essential for normal glucose homoeostasis. There is much interest in the use of GLP-1 to treat diabetes, since the risk of hypoglycaemia is thought to be low. We report an instance of a 45-year-old woman with a GLP-1 and somatostatin secreting neuroendocrine tumour who presented with reactive hypoglycaemia and hyperglycaemia, but who was subsequently cured by surgery. This case, of a neuroendocrine tumour secreting GLP-1 and causing reactive hypoglycaemia, indicates a potential adverse effect of GLP-1 therapy for diabetes.

    Topics: Blood Glucose; Carcinoid Tumor; Diabetes Complications; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hypoglycemia; Hysterectomy; Middle Aged; Ovarian Neoplasms; Peptide Fragments; Protein Precursors; Somatostatin

2003